|
1) Kripke DF, Garfinkel L, Wingard DL, et al. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry. 2002; 59: 131-6
|
|
|
|
2) Tamakoshi A, Ohno Y. Self-reported sleep duration as a predictor of all-cause mortality: results from the JACC study, Japan. Sleep. 2004; 27: 51-4
|
|
|
|
|
|
3) Taheri S, Lin L, Austin D, et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLOS Medicine. 2004; 3: 210-7
|
|
|
|
|
|
4) Ayas NT, White DP, Manson JE, et al. A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med. 2003; 163: 205-9
|
|
|
|
|
|
5) NHK放送文化研究所. 2005年国民生活時間調査報告書
|
|
|
|
|
|
6) Kripke D, Simons RN, Garfinkel L, et al. Short and long sleep and sleeping pills. Is increased mortality associated？ Arch Gen Psychiatry. 1979; 36: 103-16
|
|
|
|
|
|
7) National Sleep Foundation. Survey: Sleep in America, 1995
|
|
|
|
|
|
8) National Center for Health Statistics. QuickStats: Percentage of adults who reported an average of ≦6 hours of sleep 24-hour period, by sex and age group- United States, 1985 and 2004. Morb Mortal Wkly Rep. 2005
|
|
|
|
|
|
9) Van Cauter E, Holmback U, Knutson K, et al. Impact of sleep and sleep loss on neuroendocrine and metabolic function. Horm Res. 2007; 67 Suppl 1: 2-9
|
|
|
|
|
|
10) Spiegel K, Knutson K, Leproult R, et al. Sleep loss: a novel risk factor for insulin resitance and Type 2 diabetes. J Appl Physiol. 2005; 99: 2008-19
|
|
|
|
|
|
11) Knutson KL, Spiegel K, Penev P, et al. The metabolic consequences of sleep deprivation. Sleep Med Rev. 2007; 11: 163-78
|
|
|
|
|
|
12) 永井道明, 他. 休養・睡眠管理の技法. 循環器科. 2007; 61: 250-6
|
|
|
|
|
13) 内山 真. 不眠・睡眠不足とメタボリックシンドローム. 医学のあゆみ. 2007; 223: 837-41
|
|
|
|
|
14) Gangwisch JE, Heymsfield SB, Boden-Albala B, et al. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension. 2006; 47: 833-9
|
|
|
|
|
|
15) Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002; 418: 935-41
|
|
|
|
|
|
16) Yaggi HK, Araujo AB, Mckinlay JB. Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care. 2006; 29: 657-61
|
|
|
|
|
|
17) Knutson KL, Ryden AM, Mander BA, et al. Role of sleep duration and quality in the risk and severity of type 2 diabetes mellitus. Arch Intern Med. 2006; 166: 1768-74
|
|
|
|
|
|
18) Nilsson PM, Roost M, Engstrom G, et al. Incidence of diabetes in middle-aged men is related to sleep disturbances. Diabetes Care. 2004; 27: 2464-9
|
|
|
|
|
|
19) Mallon L, Broman JE, Hetta J. High incidence of diabetes in men with sleep complaints or short sleep duration: a 12-year follow-up study of a middle-aged population. Diabetes Care. 2005; 28: 2762-7
|
|
|
|
|
|
20) Nakajima H, Kaneita Y, Yokoyama E, et al. Association between sleep duration and hemoglobin A1c level. Sleep Med. 2008; 9: 745-52
|
|
|
|
|
|
21) Bodosi B, Gardi J, Hajdu I, et al. Rhythms of ghrelin, leptin, and sleep in rats: effects of the normal diurnal cycle, restricted feeding, and sleep deprivation. Am J Physiol Regul Integr Comp Physiol. 2004; 287: R1071-9
|
|
|
|
|
|
22) Laposky AD, Bass J, Kohsaka A, et al. Sleep and circadian rhythms: key components in the regulation of energy metabolism. FEBS Lett. 2008; 582: 142-51
|
|
|
|
|
|
23) Spiegel K, Leproult R, Cauter EV. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999; 354: 1435-9
|
|
|
|
|
|
24) Spiegel K, Tasali E, Penev O, et al. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004; 141: 846-50
|
|
|
|
|
|
25) 関根道和. 子どもの睡眠と生活習慣病—寝ぬ子は太る. 医学のあゆみ. 2007; 223: 833-6
|
|
|
|
|
|
26) Hashimoto S, Nakamura K, Honma S, et al. Free-running circadian rhythm of melatonin in a sighted man despite a 24-hour sleep pattern: a non-24-hour circadian syndrome. Psychiatry Clin Neurosci. 1997; 51: 109-14
|
|
|
|
|
|
27) 本間研一. 睡眠と臓器との関連性から生活習慣病との接点を探る. In: 清水徹男, 編. 睡眠障害治療の新たなストラテジー—生活習慣病からみた不眠症治療の最前線—. 1版. 東京: 先端医学社; 2006. p. 16-21
|
|
|
|
|
|
28) 高橋正也. 概日リズム睡眠障害群(Circadian Rhythm Sleep Disorders)概日リズム睡眠障害—交替勤務型(交替勤務制障害)—. 日本臨牀. 2008; 66 増刊号2: 341-4
|
|
|
|
|
|
29) Yamazaki S, Numano R, Abe M, et al. Resetting central and peripheral circadian oscillators in transgenic rats. Science. 2000; 288: 682-5
|
|
|
|
|
|
30) Stokkan KA, Yamazaki S, Tei H, et al. Entrainment of the circadian clock in the liver by feeding. Science. 2001; 291: 490-3
|
|
|
|
|
|
31) King DP, Zhao Y, Sangoram AM, et al. Positional cloning of the mouse circadian clock gene. Cell. 1997; 89: 641-53
|
|
|
|
|
|
32) Debruyne JP, Noton E, Lambert CM, et al. A clock shock: mouse CLOCK is not required for circadian oscillator function. Neuron. 2006; 50: 465-77
|
|
|
|
|
|
33) Shimba S, Ishii N, Ohta Y, et al. Brain and muscle Arnt-like protein-1 (BMAL1), a component of the molecular clock, regulates adipogenesis. Proc Natl Acad Sci U S A. 2005; 102: 12071-6
|
|
|
|
|
|
34) Turek FW, Joshu C, Kohsaka A, et al. Obesity and metabolic syndorome in circadian clock mutant mice. Science. 2005; 308: 1043-5
|
|
|
|
|
|
35) Ishida N. Circadian clock, cancer and lipid metabolism. Neurosci Res. 2007; 57: 483-90
|
|
|
|
|
|
36) Shirai H, Oishi K, Kudo T, et al. PPARα is a potential therapeutic target of drugs to treat circadian rhythm sleep disorders. Biochem Biophys Res Commun. 2007; 357: 679-82
|
|
|
|
|
|
37) 産業技術総合研究所. 高脂血症治療薬による睡眠障害の新しい治療効果—フィブレート製剤による体内時計の制御—. http://www.aist.go.jp/aist_j/press_release/pr2007/pr20070425/pr20070425.html
|
|
|
|
|